Contact
searchSearch
HMP Global
Login

Biomarker Testing Topic Center

Featured

David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Review
NGS Testing in Non–Small Cell Lung Cancer
09/19/2023
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon...
09/19/2023
Journal of Clinical Pathways
NGS Institute
The NGS Institute: Advancing the Appropriate Use of Biomarker Testing
02/06/2023
The NGS Institute is a trusted resource for curated, practical information on biomarker and next-generation sequencing testing. This article outlines the aim the Institute has to play a role in facilitating the integration of genomic-level...
The NGS Institute is a trusted resource for curated, practical information on biomarker and next-generation sequencing testing. This article outlines the aim the Institute has to play a role in facilitating the integration of genomic-level...
The NGS Institute is a trusted...
02/06/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Dan Rhodes, PhD
Podcasts
Episode 5: Cancer Genomics and Genetic Testing in the Era of Precision Medicine: What is a Precision Model of Care?
10/31/2022
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes,...
10/31/2022
Journal of Clinical Pathways
News
State Legislative Trends in Biomarker Testing
09/20/2022
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
Mismatch Repair/Microsatellite Instability Biomarker Testing Utilization in Advanced Colorectal Cancer
09/20/2022
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study...
09/20/2022
Journal of Clinical Pathways
News
Factors Associated With Receipt of Biomarker Testing Among Patients With Metastatic Colorectal Cancer
09/20/2022
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in...
09/20/2022
Journal of Clinical Pathways
News
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers
09/19/2022
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study...
09/19/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

News

News
State Legislative Trends in Biomarker Testing
09/20/2022
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that advocacy efforts from patient advocates, health care professionals, and professional societies are necessary at the state level to increase access to biomarker testing.
A recent publication argues that...
09/20/2022
Journal of Clinical Pathways
News
Mismatch Repair/Microsatellite Instability Biomarker Testing Utilization in Advanced Colorectal Cancer
09/20/2022
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study revealed opportunities for enhancing rates of DNA mismatch repair/microsatellite instability testing and reporting, possibly by way of integration into quality control and accreditation metrics.
Findings from a recently study...
09/20/2022
Journal of Clinical Pathways
News
Factors Associated With Receipt of Biomarker Testing Among Patients With Metastatic Colorectal Cancer
09/20/2022
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in somatic biomarker testing across subgroups of patients with metastatic colorectal cancer and identification of genomic alterations can aid in ascertaining targeted treatment and in enhancing clinical outcomes.
Significant variations exist in...
09/20/2022
Journal of Clinical Pathways
News
Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers
09/19/2022
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study suggest disparities in next-generation sequencing-based testing rates between Black and White patients with non-small cell lung cancer or metastatic colorectal cancer.
Findings from a recent study...
09/19/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
News
Outcomes of Patients With NSCLC Participating in Medicaid vs Commercial Insurance
06/12/2022
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study...
06/12/2022
Journal of Clinical Pathways
News
Artificial Intelligence-Powered Spatial Analysis of TILs Predicts Treatment Outcomes With ICIs in NSCLC
05/16/2022
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
Biomarker Testing Rates and Turnaround Times for Patients With NSCLC Receiving First-Line Therapy in The US Oncology Network
04/01/2022
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
Harnessing the Potential of Abemaciclib in Recurrent Endometrial Cancer Treatment
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
Pembrolizumab Plus Adjuvant Chemotherapy for Newly Diagnosed High-Risk dMMR Endometrial Cancer
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
False Negatives More Prevalent in Endometrial Cancer Screening for Black Women
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
Efficacy of Momelotinib in Managing Anemia in Myelofibrosis: Results from the SIMPLIFY-2 Trial
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

Video

David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Nicholas Robert, MD
Videos
Identifying Predictors of Biomarker Testing in Metastatic Non-Small Cell Lung Cancer
07/05/2022
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses real-world biomarker testing rates for metastatic non–small cell lung cancer within The US Oncology Network, examining patient factors associated with rates of biomarker testing.
Nicholas Robert, MD, discusses...
07/05/2022
Journal of Clinical Pathways
Alicia Morgans, MD, MPH, Dana-Farber Cancer Institute
Videos
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
01/12/2022
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer for...
Atish Choudhury, MD, PhD, and...
01/12/2022
Journal of Clinical Pathways
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
Videos
Biomarker-Guided First-Line Maintenance Therapy in Advanced Ovarian Cancer: Real-World Outcomes and Cost
04/27/2021
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS, details a study comparing clinical outcomes and costs with a biomarker-guided approach and non-biomarker guided approach to first-line maintenance therapy for advanced ovarian cancer.
Daniel Simmons, PharmD, MS,...
04/27/2021
Journal of Clinical Pathways
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
Navigating Payer Challenges in Cell and Gene Therapy
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology
Mariana Gouveia, MD, DASA Oncologia
Videos
Antibody-Drug Conjugates for Endometrial Cancer
10/10/2024
Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.
Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.
Mariana Gouveia, MD, gives an...
10/10/2024
Oncology
Abigail Zamorano, MD, MPHS, UT Health Houston
Videos
Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer
10/08/2024
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.
Abigail Zamorano, MD, MPHS,...
10/08/2024
Oncology
BDHC thumbnail
Breaking Down Health Care
Maximizing the Potential of Precision Medicine
10/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the economic challenges of precision medicine in health care, including the differences between Medicare and commercial health plans and...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the economic challenges of precision medicine in health care, including the differences between Medicare and commercial health plans and...
In this Breaking Down Health...
10/07/2024
Cancer Care Business Exchange

From the Journal

Trending From ACCC
ACCC Releases Biomarker Testing Implementation Roadmap
11/16/2021
The ACCC released an innovative learning tool that helps multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
The ACCC released an innovative learning tool that helps multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
The ACCC released an innovative...
11/16/2021
Journal of Clinical Pathways
Perspectives
Facing Cancer as a Chronic Disease: Shared Decision-Making at Critical Points in a Long Illness Journey
10/01/2024
In this third installment of a three-part series on decision support tools and shared decision-making, Christine Wilson, MA, MS, and colleagues describe how patients with­in three diverse communities who are living with cancer understand and...
In this third installment of a three-part series on decision support tools and shared decision-making, Christine Wilson, MA, MS, and colleagues describe how patients with­in three diverse communities who are living with cancer understand and...
In this third installment of a...
10/01/2024
Journal of Clinical Pathways
Perspectives
Who Uses Pathways Around Care Management?
10/01/2024
This pilot study provides a brief literature review on users, uses, and a recent electronic survey to de­termine how users use clinical pathways along with their feedback around their value.
This pilot study provides a brief literature review on users, uses, and a recent electronic survey to de­termine how users use clinical pathways along with their feedback around their value.
This pilot study provides a...
10/01/2024
Journal of Clinical Pathways
Research Reports
Time to Treatment and the “Golden Hour”: Why They Matter and How Clinical Pathways Can Help
08/19/2024
This study explores how clinical pathways can help reduce time to treatment delays while improving health care quality, lowering direct and indirect health care costs, reducing patient financial toxicity, and achieving greater patient,...
This study explores how clinical pathways can help reduce time to treatment delays while improving health care quality, lowering direct and indirect health care costs, reducing patient financial toxicity, and achieving greater patient,...
This study explores how clinical...
08/19/2024
Journal of Clinical Pathways
From the Field
Bridging the Gap Between Oncologists and Payers: Impact of an EHR-Embedded CDS Tool in Oncology Clinical Pathway (OCP) Adherence
08/15/2024
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers discuss a real-world study of treatment selection patterns across American Oncology Network medical oncologists, which analyzed pathway adherence rates before and after a pilot project where Evolent level 1...
In this report, researchers...
08/15/2024
Journal of Clinical Pathways
Perspectives
Individualized Care Through Treatment Pathways: Isn’t This an Oxymoron?
06/26/2024
This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.
This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.
This article describes how...
06/26/2024
Journal of Clinical Pathways
From the Field
Shifting the Paradigm: The Impact of AI at the Point of Care in Cancer Treatment
06/03/2024
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the transformative impact of artificial intelligence (AI) in health care, emphasizing its potential paradigm shift and current deployment in oncology.
This report explores the...
06/03/2024
Journal of Clinical Pathways
Research Reports
PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing
06/03/2024
Sabree C. Burbage, PharmD
Dexter Waters, MSPH
Carmine Rossi, PhD
Frederic Kinkead, MA
Erik Muser, PharmD
Lorie Ellis, PhD
Patrick Lefebvre, MA
Dominic Pilon, MA
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes...
06/03/2024
Journal of Clinical Pathways
From the Field
Bringing Value to Health Care
06/03/2024
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US.
This paper provides insights and...
06/03/2024
Journal of Clinical Pathways
Research Reports
Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results
02/21/2024
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann...
02/21/2024
Journal of Clinical Pathways
From the Field
Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
02/12/2024
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al provide an overview of current genomic testing methodologies and offer guidelines on best practices for tissue stewardship and preanalytic practices for successful comprehensive genomic profiling.
Rebecca A. Previs, MD, et al...
02/12/2024
Journal of Clinical Pathways

Conference Coverage

Conference Coverage
BRCA Variants in Patients With Ovarian Cancer and the Risk of Adverse Reactions
06/10/2022
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at the 2022 ASCO Annual Meeting found that BRCA variants may not increase the risk of adverse reactions among patients with ovarian cancer.
A real-world study presented at...
06/10/2022
Journal of Clinical Pathways
Conference Coverage
Factors Predicting the Likelihood of Undergoing Biomarker Testing in Ovarian Cancer
06/08/2022
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented at ASCO 2022, only 55% of patients with ovarian cancer underwent biomarker testing due to factors such as insurance type, ECOG status, and region.
According to findings presented...
06/08/2022
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting
12/07/2021
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Recent Advancements in Biomarker Testing and Therapeutic Strategies in Oncology
05/03/2021
05/03/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
04/07/2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker...
04/07/2021
Journal of Clinical Pathways
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
02/03/2021
02/03/2021
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Conference Coverage
Oncology Pathways Research: Challenges, Adoption, and Future Trends
11/08/2024
In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...
In an exclusive interview with the Journal of Clinical Pathways, Cindy Chen, Head of Research at HMP Market Access Insights, shares insights into the challenges, adoption, and future trends of oncology pathways research. Her discussion draws...
In an exclusive interview with...
11/08/2024
Journal of Clinical Pathways
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
News
Palliative Care Needs in Patients With Small Cell Lung Cancer and Caregivers: Survey Insights
10/16/2024
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...
A study presented at the 2024...
10/16/2024
Journal of Clinical Pathways
News
CPC + CBEx 2024: Influence and Impact of Oncology Pathways
09/25/2024
HMP Market Access Insights researchers shared their findings on the impact of pathway programs on treatment selections at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
HMP Market Access Insights researchers shared their findings on the impact of pathway programs on treatment selections at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
HMP Market Access Insights...
09/25/2024
Journal of Clinical Pathways
Conference Coverage
CPC + CBEx 2024: Integration of Medical Oncology and Surgical Specialties
09/19/2024
Presenters at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange shared how their institutions integrate medical oncology and surgical specialties for genitourinary cancers and some of the challenges they face both clinically...
Presenters at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange shared how their institutions integrate medical oncology and surgical specialties for genitourinary cancers and some of the challenges they face both clinically...
Presenters at the 2024 Clinical...
09/19/2024
Journal of Clinical Pathways
Conference Coverage
CPC + CBEx 2024: Pathways for Social Needs Assessment and Care
09/18/2024
In a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange, experts went over the importance of social needs assessment and care in oncology and provided an example of pathways that help in providing these services to...
In a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange, experts went over the importance of social needs assessment and care in oncology and provided an example of pathways that help in providing these services to...
In a session at the 2024...
09/18/2024
Journal of Clinical Pathways
Conference Coverage
CPC + CBEx 2024: Managing Clinical & Financial Risk in Oncology
09/13/2024
A group of oncology practice innovators and care platform disruptors spoke about managing clinical and financial risk in oncology as part of a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
A group of oncology practice innovators and care platform disruptors spoke about managing clinical and financial risk in oncology as part of a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
A group of oncology practice...
09/13/2024
Journal of Clinical Pathways
Conference Coverage
CPC + CBEx 2024: Strategies for Patient Navigation Services
09/12/2024
Learn about different implementation strategies for patient navigation presented at a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
Learn about different implementation strategies for patient navigation presented at a session at the 2024 Clinical Pathways Congress + Cancer Care Business Exchange.
Learn about different...
09/12/2024
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Review
NGS Testing in Non–Small Cell Lung Cancer
09/19/2023
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon...
09/19/2023
Journal of Clinical Pathways
NGS Institute
The NGS Institute: Advancing the Appropriate Use of Biomarker Testing
02/06/2023
The NGS Institute is a trusted resource for curated, practical information on biomarker and next-generation sequencing testing. This article outlines the aim the Institute has to play a role in facilitating the integration of genomic-level...
The NGS Institute is a trusted resource for curated, practical information on biomarker and next-generation sequencing testing. This article outlines the aim the Institute has to play a role in facilitating the integration of genomic-level...
The NGS Institute is a trusted...
02/06/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Dan Rhodes, PhD
Podcasts
Episode 5: Cancer Genomics and Genetic Testing in the Era of Precision Medicine: What is a Precision Model of Care?
10/31/2022
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes, PhD, discuss genomic testing and next-generation sequencing, the available technologies advancing the precision model of care, and exciting steps forward in the rapidly evolving oncology treatment landscape.
Gordon Kuntz and Dan Rhodes,...
10/31/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use